Treatment of non-small-cell lung cancer (NSCLC) has entered the immunotherapy era, marked by significant survival improvements due to the use of immune checkpoint inhibitors (ICIs). However, owing to factors, such as disease progression, long-term use, and side effects, some patients discontinue immunotherapy, resulting in limited subsequent treatment option and a negative impact on their survival and quality of life. We have collected relevant data which reveal that ICI rechallenge may be an effective clinical strategy. However, many factors affect the efficacy of rechallenge, including patient characteristics, initial treatment drugs, treatment duration, efficacy, toxicity, and side effects. Additionally, the side effects of rechallenge and mechanisms of reversing drug resistance play crucial roles. Identifying suitable candidates, optimizing treatment plans and duration, enhancing treatment efficacy, and minimizing toxicity and adverse effects in rechallenges are pressing clinical needs. Addressing these issues can provide guidance for the clinical use of immunotherapy rechallenges to better serve patients. This review focuses on the clinical considerations and strategies for immune therapy rechallenges in NSCLC.
Our study aimed to explore how DEK, a carcinogenic protein with chromatin architectural function, genome-widely binds to RNA and affects the alternative splicing in cancer cells to decipher its molecular functions. To achieve this goal, cell phenotype experiments, RNA sequencing (RNA-seq), and improved RNA immunoprecipitation sequencing (iRIP-seq) were conducted to identify the function and regulated targets of DEK in HeLa cells. The results showed DEK overexpression promoted cell proliferation and invasion of HeLa cells. Meanwhile, DEK hardly affected transcript level expression of those high expressed genes, but splicing pattern of 411 genes was regulated by DEK in HeLa cells, which were enriched in Hippo signaling pathway. Moreover, DEK broadly bind the RNA of a total of 11, 112 genes, with a biased binding the 5' splice site (5'SS) consensus GGUAA motifs at the CDS and intronic regions. In addition, 297 DEK-binding genes showed different splicing pattern after DEK overexpression in HeLa cells. These genes were enriched in Hippo signaling pathway including CSNK1D. The RT-qPCR and RIP-PCR confirmed that DEK can bind to CSNK1D to regulate its alternative splicing in HeLa cells. In summary, our results indicated DEK could broadly bind and regulate the pre-mRNA splicing process, which provide new insights of mechanisms that DEK functions in various biological processes including cancer.
Thoracic SMARCA4-deficient undifferentiated tumour(SMARCA4-UT) is a newly classified subgroup of non-small cell lung cancer (NSCLC) that is rare and associated with a poor prognosis. There is a paucity of robust research regarding its treatment options and prognostic assessment. Generally, the first-line treatments for NSCLC patients with SMARCA4 are similar to those for soft tissue sarcoma (STS). STS is partially insensitive to chemotherapy and lacks specific targeted therapeutic interventions. Consequently, the immunotherapy is increasingly applied as the first-line treatment. This paper described the treatment process of two SMARCA4 patients receiving a combination of chemotherapy and immunotherapy, employing T-cell Receptor-sequencing technology(TCR). From the perspective of the immune microenvironment, we propose a novel potential marker—TCR—that may serve as an indicator for prognostic evaluation of immunotherapy in SMARCA4 patients, thereby providing a theoretical foundation from the perspectives of tissue and peripheral immunity.
Authors Yiwei Zhou and Qijiao Li are employed by Kindstar Global Precision Medicine Institute. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.As an author of the aforementioned manuscript, I hereby solemnly declare: I have fully understood and agreed to the above author list correction, including the revised author order, equal contribution label, and affiliation information, with no objections; I confirm that Xiayu Wang and Yiwei Zhou undertook core work in "conceptualization, writing the original draft, and manuscript revision" during the research, which meets Frontiers' criteria for first authorship;This correction is a result of unanimous consultation among the author team, with no academic misconduct (e.g., unauthorized addition/removal of authors, falsification of contribution attribution), and complies with Frontiers' Authorship Policy and ICMJE Guidelines;Any academic disputes or controversies arising from this correction shall be borne by all authors, and the journal shall not be held liable.